ArticleHistopathology2026
Bronchiolar adenoma and glandular papilloma/mixed squamous cell and glandular papilloma represent a continuous disease spectrum: revelations from combined histological and genetic analysis.
Article in Histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsDespite their common bronchial/bronchiolar origin, the relationship between glandular/mixed papillomas (GPs/MPs) and bronchiolar adenomas (BAs) remains uncertain; therefore, this study aimed to elucidate it. METHODS AND
resultsWe performed a combined clinicopathological and next-generation sequencing analysis of 6 GP/MP and 14 BA cases. The cases were classified into three groups based on histopathological features: Group A (classic GP/MP), Group B (transitional morphology) and Group C (glandular predominant BA, lacks papillary structure). Analysis revealed a morphological continuum from Group A to Group C, characterized by a gradual transition from endobronchiolar papillary growth to alveolar glandular structures and a shift in the lining epithelium from pseudostratified ciliated columnar to cuboidal/flat. Clinically, compared with Group C, Group A showed a higher proportion of males and larger tumour size, while Group B exhibited intermediate features. Genetically, GP/MP frequently harboured BRAF (83.3%) and AKT1 (66.6%) mutations, whereas BAs displayed a more diverse profile, including BRAF (28.5%), AKT1 (21.4%), EGFR (28.5%) and KRAS (14.2%) mutations. BRAF and AKT1 mutations were predominantly found in Groups A and B, whereas EGFR and KRAS mutations were more common in Group C.
conclusionGP/MP and BA represent the same disease spectrum, showing a continuous histomorphological change along the proximal-to-distal bronchial tree. BRAF and AKT1 mutations are more frequently observed in GP/MP and proximal-type BA with papillary architecture, whereas BA lacking papillary structures is mainly characterized by EGFR or KRAS mutations. However, the BRAF mutation rate in BA varies across geographical regions and appears to be associated with factors such as smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.